Cara Therapeutics, Inc. (CARA)
Stock Price:
$14.24 USD
-0.05 (-0.35%)
Updated Oct 23, 2020 12:41 PM EDT - Market open
Key Info
| Market Cap |
667.67M |
| Revenue (ttm) |
24.02M |
| Net Income (ttm) |
-115.44M |
| Shares Out |
46.89M |
| EPS (ttm) |
-2.50 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 23, 2020 |
| Last Price |
$14.24 |
| Previous Close |
$14.29 |
| Change ($) |
-0.05 |
| Change (%) |
-0.35% |
| Day's Open |
14.40 |
| Day's Range |
14.10 - 14.54 |
| Day's Volume |
164,966 |
| 52-Week Range |
8.88 - 26.67 |
More Stats
| Market Cap |
667.67M |
| Enterprise Value |
541.04M |
| Earnings Date (est) |
Oct 29, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
46.89M |
| Float |
42.88M |
| EPS (basic) |
-2.51 |
| EPS (diluted) |
-2.50 |
| FCF / Share |
-2.62 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
4.41M |
| Short Ratio |
10.64 |
| Short % of Float |
10.27% |
| Beta |
1.68 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
27.79 |
| PB Ratio |
4.70 |
| Revenue |
24.02M |
| Operating Income |
-120.29M |
| Net Income |
-115.44M |
| Free Cash Flow |
-122.76M |
| Net Cash |
126.63M |
| Net Cash / Share |
2.70 |
| Gross Margin |
-391.02% |
| Operating Margin |
-500.72% |
| Profit Margin |
-480.60% |
| FCF Margin |
-511.00% |
| ROA |
-47.25% |
| ROE |
-96.01% |
| ROIC |
-77.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (8)
| Buy |
7 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$33.00*
(131.74% upside)
Low
18.0
Current: $14.24
High
40.0
Target: 33.00
*Average 12-month price target from 8 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | 19.89 | 13.47 | 0.91 | 0.09 | 3.80 | 3.18 | 11.96 | 1.19 | - |
| Revenue Growth | 47.64% | 1378.49% | 959.3% | -97.74% | 19.7% | -73.45% | 905.38% | - | - |
| Gross Profit | 19.89 | 13.47 | 0.91 | 0.09 | 3.80 | 3.18 | 11.96 | 1.19 | - |
| Operating Income | -112 | -77.38 | -59.49 | -58.40 | -25.19 | -18.07 | -0.24 | -6.24 | -9.75 |
| Net Income | -106 | -74.01 | -58.13 | -57.28 | -24.69 | -17.75 | -3.96 | -6.27 | -9.81 |
| Shares Outstanding | 42.67 | 35.89 | 31.20 | 27.28 | 24.62 | 20.97 | 4.13 | 3.30 | 3.24 |
| Earnings Per Share | -2.49 | -2.06 | -1.86 | -2.10 | -1.00 | -0.85 | -0.74 | -1.90 | -3.03 |
| Operating Cash Flow | -109 | -22.30 | -54.83 | -47.38 | -21.48 | -17.64 | 2.83 | -6.03 | -6.85 |
| Capital Expenditures | -0.02 | -0.07 | -0.02 | -0.72 | -0.02 | -0.04 | -0.01 | 0.51 | 0.05 |
| Free Cash Flow | -109 | -22.37 | -54.84 | -48.10 | -21.50 | -17.68 | 2.82 | -5.52 | -6.80 |
| Cash & Equivalents | 155 | 162 | 93.34 | 59.75 | 107 | 53.36 | 13.06 | 1.82 | 5.09 |
| Total Debt | 4.32 | - | - | - | - | - | - | 0.78 | 0.75 |
| Net Cash / Debt | 151 | 162 | 93.34 | 59.75 | 107 | 53.36 | 13.06 | 1.04 | 4.34 |
| Assets | 233 | 191 | 97.00 | 63.83 | 111 | 55.93 | 18.08 | 5.54 | 10.69 |
| Liabilities | 46.25 | 57.19 | 10.22 | 13.10 | 5.85 | 4.27 | 72.16 | 63.67 | 62.75 |
| Book Value | 187 | 134 | 86.78 | 50.73 | 105 | 51.66 | -54.08 | -58.13 | -52.06 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Cara Therapeutics, Inc. |
| Country |
United States |
| Employees |
72 |
| CEO |
Derek T. Chalmers |
Stock Information
| Ticker Symbol |
CARA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CARA |
| IPO Date |
January 31, 2014 |
Description
Cara Therapeutics, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) undergoing hemodialysis. The company is also developing Oral KORSUVA (CR845/difelikefalin), which has completed Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; in Phase II clinical trial for treating pruritus chronic liver disease; and in Phase II clinical trial for the treatment of pruritus associated with atopic dermatitis. In addition, it is developing CR845/difelikefalin Injection, which has completed Phase II/III clinical trial for the treatment of acute post-operative pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.